#Europe

Listen to personal tales from the global urban AIDS response, including reports from five U.S. cities.

A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)

The longer people in a British study had been living with diagnosed HIV, the more likely they were to have depression and anxiety.

A recent survey of such sites found high rates of hepatitis C among patrons, but treatment for the virus was rarely offered on-site.

One percent of gay and bi men in a Dutch PrEP study contracted hepatitis C annually; of those cured, one in four were reinfected per year.

Among a group of largely HIV-positive gay and bi men, Zepatier (grazoprevir/elbasvir) boasted a 99 percent cure rate.

The newly released PARTNER2 study documented 77,000 condomless anal sex acts between mixed-HIV-status men; Opposites Attract had 12,000.

A study comparing on-demand and daily PrEP has seen lower side effects with daily use and an overall trend of increased sexual risk-taking.

This is according to an analysis of multiple factors potentially related to a diabetes diagnosis in a large group of French people with HIV.

Researchers identified treatment with Kaletra (lopinavir/ritonavir) as a risk factor.

This is according to a meta-analysis of a dozen studies conducted in North America and Europe.

The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.

However, two similar cases have been reported in Australia.

In a recent study of more than 600 HIV-positive adults, 93 percent were cured of hep C.

A recent study of Dutch clinicians found that they generally did a good job of preventing drug-drug interactions.

U.K. public health officials have expressed great concern over this latest sign of evolution of the sexually transmitted infection.